ÂÜŔňÂŇÂ×

Edward Garmey, M.D., is interim Chief Medical Officer of Tarveda. A former academic hematologist-oncologist, Edward Garmey has served as Chief Medical Officer for leading private and public biopharmaceutical companies and has spent several years in a consulting capacity during his 15 years in the industry. Most recently, Dr. Garmey served as Chief Medical Officer and Senior Vice President at Cerulean Pharma where he oversaw the initiation of multi-national clinical trials for multiple drug programs and helped lead the company’s successful $67 million IPO. Previously, Dr. Garmey served as a pediatric hematologist-oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC). He is an alumnus of Harvard and New York Universities and completed his medical training at New York’s Mount Sinai Medical Center, the Children’s Hospital of Los Angeles, and MSKCC. Dr. Garmey completed additional research fellowships at the National Institutes of Health and the Botswana-Harvard Partnership for H.I.V. Research in Gaborone, Botswana and he is the recipient of the young investigator's awards from the American Society of Hematology and the American Heart Association. Dr. Garmey serves as an adjunct instructor at Harvard Medical School’s Graduate Program in Therapeutic Science and as a member of the Board of Overseers at the Beth Israel Deaconess Medical Center.